
Alnylam and Inceptive land up to $2 billion AI RNA deal
The pact could speed RNA drug discovery, showing how AI is becoming a core tool in biotech dealmaking, not just a lab experiment.
By Mohammed Al-Shehri·· 3 min
4 briefings · “science”

The pact could speed RNA drug discovery, showing how AI is becoming a core tool in biotech dealmaking, not just a lab experiment.

A Science study says bumblebees can tackle a box-and-banana style puzzle on their own, a clue that even tiny-brained creatures may handle novel tasks without being taught.

The quantum computing company chose a traditional IPO over the SPAC-heavy path, signaling a bid for mainstream credibility that other founders and boards will be watching closely.

The startup's physics simulation platform aims to close the gap between molecular structure and real-world behavior, a blind spot that costs pharma and materials companies billions.